Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Neil Exter
AddedMar 31, 2024
UpdatedMay 31, 2026
Neil Exter

Neil Exter

Board Member, New England Venture Capital Association

Crunchbase

Neil Exter's Career

New England Venture Capital Association
New England Venture Capital Association

Boston, MA, US

Board Member· Board
Pliant Therapeutics
Pliant Therapeutics

South San Francisco, CA, US

Board Member· Board
Cibiem
Cibiem

Los Altos, CA, US

Board Member· Board
Cedilla Therapeutics
Cedilla Therapeutics

Cambridge, MA, US

Board Member· Board
Celsius Therapeutics
Celsius Therapeutics

Cambridge, MA, US

Board Member· Board
Thrive Earlier Detection
Thrive Earlier Detection

Cambridge, MA, US

Board Member· Board
Goldfinch Bio
Goldfinch Bio

Cambridge, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Neil Exter's Career

New England Venture Capital Association
New England Venture Capital Association
Investment FirmInvestment Firm131902Boston, MA, US
Board Member· Board

Leadership at New England Venture Capital Association

Lily LymanLily LymanBoard Member
Jeff BussgangJeff BussgangBoard Member
Stephen KrausStephen KrausBoard Member
Kevin BittermanKevin BittermanBoard Member
Marian NakadaMarian NakadaBoard Member
Colleen CuffaroColleen CuffaroBoard Member
Pliant Therapeutics
Pliant Therapeutics
Public$694.9M1242015South San Francisco, CA, US
Board Member· Board

Leadership at Pliant Therapeutics

David PyottDavid PyottBoard Member
Smital ShahSmital ShahBoard Member
Charles HomcyCharles HomcyBoard Member
Perry KarsenPerry KarsenBoard Member
Katharine KnobilKatharine KnobilBoard Member
Suzanne BruhnSuzanne BruhnBoard Member
Cibiem
Cibiem
Acquired$13M02010Los Altos, CA, US
Board Member· Board

Leadership at Cibiem

Paul LaviolettePaul LavioletteBoard Member
Howard LevinHoward LevinCo-Founder
Mark GelfandMark GelfandCo-Founder
Hank KuchemanHank KuchemanBoard Member
Ken MartinKen MartinCEO

Similar to Cibiem

Niche BiomedicalNiche BiomedicalLos Angeles, CA, USMedical Devicesest. 2016Niche BiomedicalLos Angeles, CA, US · est. 2016

Niche Biomedical: Innovating neuromodulation devices for enhanced human health.

Pre-Seed · $1.4M15
NeuroBionicsNeuroBionicsSeattle, WA, USMedical DevicesNeuroBionicsSeattle, WA, US

Developing medical devices for neurological disorders.

Series A · $6M6
SeaStar MedicalSeaStar MedicalAnn Arbor, MI, USMedical Devicesest. 2007SeaStar MedicalAnn Arbor, MI, US · est. 2007

CytoPherx Inc. offers proprietary medical devices for treating inflammation-based diseases.

Series C · $50.2M5
ClarimedixClarimedixBoulder, CO, USMedical Devicesest. 2006ClarimedixBoulder, CO, US · est. 2006

Clarimedix, Inc., a US-based medical device company, specializes in treating vascular dysfunction.

Angel · $275k5
Cedilla Therapeutics
Cedilla Therapeutics
Series B$138.8M452018Cambridge, MA, US
Board Member· Board

Leadership at Cedilla Therapeutics

Matthew P JacobsonMatthew P JacobsonCo-Founder
Eli CasdinEli CasdinBoard Member
Abbie CelnikerAbbie CelnikerBoard Member
William KaelinWilliam KaelinCo-Founder
Alan D'AndreaAlan D'AndreaCo-Founder
Steve GygiSteve GygiCo-Founder
Celsius Therapeutics
Celsius Therapeutics
Series B$148M722018Cambridge, MA, US
Board Member· Board

Leadership at Celsius Therapeutics

Tariq KassumTariq KassumCEO
Aviv RegevAviv RegevFounder
Alexis BorisyAlexis BorisyBoard Member

Similar to Celsius Therapeutics

Cedilla TherapeuticsCedilla TherapeuticsCambridge, MA, USTherapeuticsest. 2018Cedilla TherapeuticsCambridge, MA, US · est. 2018

Cedilla Therapeutics: A Massachusetts-based biotech firm innovating small molecule disease treatments.

Series B · $138.8M45
CellarityCellaritySomerville, MA, USMedicine Developmentest. 2017CellaritySomerville, MA, US · est. 2017

Cellarity, a Flagship Pioneering company, harnesses machine learning for innovative medicine development.

Series C · $294M165
Athos TherapeuticsAthos TherapeuticsTorrance, CA, USTherapeuticsest. 2019Athos TherapeuticsTorrance, CA, US · est. 2019

Athos Therapeutics: Pioneering AI-based precision treatments for autoimmune diseases and cancer.

Series A · $19.3M15
Cogent BiosciencesCogent BiosciencesWaltham, MA, USBiotech, Therapiesest. 2014Cogent BiosciencesWaltham, MA, US · est. 2014

US-based Cogent Biosciences develops biotech solutions for genetically driven diseases.

Public · $692.7M138
Thrive Earlier Detection
Thrive Earlier Detection
Late Stage Private$367M1752019Cambridge, MA, US
Board Member· Board

Leadership at Thrive Earlier Detection

Christoph LengauerChristoph LengauerCo-Founder
Steven J. KafkaSteven J. KafkaBoard Member
Isaac KindeIsaac KindeCo-Founder
Nickolas PapadopoulosNickolas PapadopoulosCo-Founder
Kenneth KinzlerKenneth KinzlerCo-Founder
Bert VogelsteinBert VogelsteinCo-Founder

Similar to Thrive Earlier Detection

Early DetectionEarly DetectionSan Diego, CA, USCancerscreeningest. 2017Early DetectionSan Diego, CA, US · est. 2017

Early Detection, founded in 2017, develops non-invasive, accurate cancer screening tests in San Diego.

Seed · $282k7
GRAILGRAILMenlo Park, CA, USCancer Detectionest. 2016GRAILMenlo Park, CA, US · est. 2016

GRAIL, Inc., a Menlo Park-based biotech firm, specializes in early cancer detection using science and technology.

Public · $2B823
FreenomeFreenomeSouth San Francisco, CA, USCancer Detectionest. 2014FreenomeSouth San Francisco, CA, US · est. 2014

Freenome, a US-based company, is dedicated to providing tools for cancer detection, treatment, and prevention.

Late Stage Private · $1.1B375
Harbinger HealthHarbinger HealthCambridge, MA, USBlood Testsest. 2018Harbinger HealthCambridge, MA, US · est. 2018

Harbinger Health: Pioneering early blood cancer detection through innovative testing.

Series B · $190M77
Goldfinch Bio
Goldfinch Bio
Public$210M412015Cambridge, MA, US
Board Member· Board

Leadership at Goldfinch Bio

Franklin MadduxFranklin MadduxBoard Member
Peter MundelPeter MundelCo-Founder
Daniel MacArthurDaniel MacArthurCo-Founder
Louis BrennerLouis BrennerBoard Member
Anthony G JohnsonAnthony G JohnsonCEO

Similar to Goldfinch Bio

Kyntra BioKyntra BioSan Francisco, CA, USPharmaceuticalsest. 1993Kyntra BioSan Francisco, CA, US · est. 1993

FibroGen, Inc: A global, research-based pharmaceutical company in San Francisco, innovating treatments for unmet medical needs.

Public · $188M592
Apic BioApic BioCambridge, MA, USBiopharmaceuticalsest. 2017Apic BioCambridge, MA, US · est. 2017

Apic Bio: A dedicated biopharmaceutical firm innovating cures for genetic diseases.

Series A · $53.3M32
BridgeBio PharmaBridgeBio PharmaPalo Alto, CA, USGenetic Medicinesest. 2015BridgeBio PharmaPalo Alto, CA, US · est. 2015

Bridgebio Pharma, a US-based biotech firm, specializes in developing medicines for genetic diseases globally.

Public · $3.6B392
Boston BiopharmaBoston BiopharmaAlpharetta, GA, USMedications, Pharmaceuticalsest. 2012Boston BiopharmaAlpharetta, GA, US · est. 2012

Boston Biopharma: US-based pioneers in specialty medications, focusing on R&D, licensing, and global distribution.

Seed · $1.5M12

Neil Exter's Similar Executives & Operators

Soemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakChi-hyung SongChi-hyung SongBoard Member · DunamuWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailJaeHong ChoiJaeHong ChoiBoard Member · KakaoMason YeoMason YeoBoard Member · Kakao

People Similar to Neil Exter

Jochen KnolleJochen KnolleBoard Member · Anchor TherapeuticsSteve NiekerSteve NiekerCo-Founder · Keep HoldingsMarc-Andre MarcotteMarc-Andre MarcotteBoard Member · CurvaFixAnthony ShuberAnthony ShuberFounder · Exact SciencesJohn CostantinoJohn CostantinoBoard Member · Bayer PharmaceuticalsJohn CiccioJohn CiccioBoard Member · OS Therapies